Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
Stopped early · Not applicable
Conditions studied: Esophageal Cancer, Gastric Cancer
In brief
The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tumor; based on the results of these tests, a patient will be assigned to a chemotherapy treatment.
Key facts
- Study ID
- NCT02358863
- Run by
- Georgetown University
- People needed
- 13
- Starts
- 2015-02-01
- Expected to finish
- 2016-11-01
- Last updated by the study team
- 2018-09-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Advanced, measurable metastatic esophagogastric adenocarcinoma by RECIST criteria
- Patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant chemotherapy (the wash-out period will be at least 1 month)
- Patients who are not eligible for resection and are chemotherapy naïve
- Patients with HER2(-) status
- Patients who have tumor deposit(s) that are easily accessible by ultrasound or CT guidance
- Patients must have adequate organ function
- Patients must provide written informed consent
You may not qualify if…
- Active concurrent malignancy, other than superficial, non-squamous cell carcinoma of the skin or uterine cervix, within the past three years
- ECOG performance status worse than 2
- Prior oral or intravenous chemotherapy for metastatic disease
- Patients with comorbidities that prevent them from being able to receive the chemotherapy regimen
- cardiac ejection fraction 45% or greater
Where it is running
- Georgetown University — Washington D.C., District of Columbia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.